Psychedelic-focused venture studio Beckley Waves has acquired digital ketamine-assisted therapy (KAT) provider Nue Life. Beckley Waves seeks to improve access to well-being-enhancing medicines and tools in an industry that is dominated by “antiquated” approaches to mental health, according to Daniel Love, co-founder and partner at Beckley Waves and interim CEO of Nue Life. “At the […]
Category: Psychedelics
London-based COMPASS Pathways plc (Nasdaq: CMPS) has secured $285 million in private funding to advance the company toward offering psychedelics as a treatment for mental health conditions. The company appears to see a clear path toward FDA approval and has convinced several investors of the opportunity. COMPASS Pathways named 11 investment firms and hinted at […]
The FDA is looking to hammer out a new pathway for studying the use of psychedelic drugs to treat behavioral health conditions. Specifically, the agency recently released a new draft guidance for the clinical development of psychedelic drugs. Although psychedelic drugs have shown promise in treating various mental health and substance use disorders, researchers have […]
Chicago-based mental health care provider Stella has acquired the majority of ketamine-assisted therapy provider Field Trip Health & Wellness Ltd’s U.S. assets. The deal gives Stella a new line of business which its CEO says complements its existing offerings. Plus, the combined Stella-Field Trip assets will generate higher revenue and lower overhead than Field Trip […]
For all the hype, psychedelics such as MDMA or psilocybin won’t succeed as a treatment or service line without substantial clinical support within behavioral health organizations. As recent ketamine-provider stumbles demonstrate, simply establishing access to and attempting to scale singular forms of treatment tend to lead to failure. Further, such treatment-specific ventures fail to address […]
Researchers pitted ketamine therapy against electroconvulsive therapy (ECT) — the so-called “gold standard” intervention for severe depression. The study found that ketamine held its own. Six months after the treatments, about half (55%) of ketamine participants experienced at least a 50% improvement in depression symptoms and quality of life measures. That number was 41% for […]
Ketamine therapy has a long way to go before it becomes a major part of the behavioral health industry. The high-profile stumbles at Field Trip Health & Wellness and Ketamine Wellness Center highlight the fraught environment the half-a-century-old drug faces in treating mental health at scale. It also illustrates the risk of moving too early […]
Psychedelic-assisted treatment provider Field Trip Health & Wellness Ltd. is on the market. This comes after the publicly traded company announced that it was not solvent and searching for a deal to stay afloat while it reorganizes its financial obligations in court. The news marks a huge stumble in a nearly $100 million endeavor to […]
A group of federal lawmakers seeks to remove regulatory barriers that inhibit psychedelics in research and compassionate use cases. Senators Cory Booker (D-N.J.) and Rand Paul (R-KY) introduced an updated version of the Breakthrough Therapies Act to the Senate. If passed, the bill would make it easier to use Schedule 1 drugs with a breakthrough […]
After years of regulatory hurdles and societal stigma, psychedelic-assisted treatment for behavioral health conditions is coming into the spotlight. The growing popularity of psychedelics is due, in part, to promising research results and multiple states relaxing regulations. Now, 2023 could be a banner year for the treatment. Psychedelic legalization is going into effect in the […]
Sign up
Receive industry updates and breaking news from Behavioral Health Business